ClinicalTrials.gg
CompletedNCT03954444Updated Jun 23, 2021Results posted

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

A Phase 3 interventional study of Oxymetazoline Hydrochloride and Rhofade Cream, 1% in Rosacea, sponsored by Actavis Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-23.

Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.

Enrollment
3rd of 137
1,105 · median 78
Started
2019
with 8 others
Phase 3
32 of 145
none open now
Registered
110th of 145
by date
Lead sponsor
5 of 145
Actavis Inc.

Among the 145 studies in Rosacea with a site in United States, this one is the 3rd largest by enrollment of the 137 interventional ones that give a count, is one of 9 that started in 2019, is one of 32 in phase 3, and was the 110th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Rosacea with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site Therapeutic Equivalence Study with Clinical End-points Comparing Test Product "Oxymetazoline hydrochloride Cream, 1%" to Reference Product "RHOFADE™ Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Study subjects must have provided IRB approved written using the latest version of the IRB informed consent form, (or assent in applicable states/countries). In addition, study subjects must sign a HIPAA authorization, if applicable.
  • (2) Healthy male or non-pregnant females, ≥18 years-of-age with a clinical diagnosis of rosacea with persistent (non-transient) facial erythema.
  • (3) Ability to follow study instructions and complete subject diary without assistance.
  • (4) Females of child bearing potential must not be pregnant or lactating at screening visit and at baseline visit, as documented by a negative urine pregnancy test.
  • (5) Female subjects of must be willing to use an acceptable form of from the day of the first dose administration to 30 days after the last administration of Product (IP). A sterile sexual partner is NOT considered an adequate form of birth control.
  • (6) Moderate to severe persistent facial erythema associated with rosacea, defined as a grade of ≥3 on the CEA scale as assessed by the Investigator at Screening and on Baseline (Day 1) visit prior to study drug application.
  • (7) Moderate to severe persistent facial erythema associated with rosacea, defined as a grade of ≥3 on the SSA scale as assessed by the subject at Screening and on Baseline (Day 1) visit prior to study drug application.
  • (8) Stable erythema (for at least 3 months prior to screening) associated with rosacea, with minimal variation from day to day and within each day, in the opinion of the subject.
  • (9) Willingness to complete the required visits including short stay for at least 12 hours at the investigational site for 2 separate visits.
  • (10) Subjects who use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens must have used the same product brands/types for a minimum period of 4 weeks prior to Baseline, must agree not to change brand/type or frequency of use throughout the study and must agree not to use make-up, facial moisturizers, creams, lotions and/or sunscreens on the scheduled clinic visit day before the visit.
  • (11) Subject must be willing to avoid the use of abrasive cleansers or washes (e.g., exfoliating facial scrubs), adhesive cleansing strips (e.g., Bioré® Pore Strips) and wax epilation on the face, during the entire duration of their study participation.
  • (12) Subject's willingness to minimize external factors that might trigger rosacea flare-ups (e.g., spicy foods, thermally hot foods and drinks, hot environments, prolonged sun exposure, strong winds, alcoholic beverages).
  • (13) Subject must be in good health and free from any systemic or dermatological disorder (other than rosacea) that, in the opinion of the Investigator, will interfere with the study evaluations or increase the risk of AEs.
  • (14) Any skin type or race, providing the skin pigmentation will allow discernment of erythema.

Exclusion criteria

Exclusion Criteria:

  • (1) Any of the following conditions: severe or unstable or uncontrolled cardiovascular disease, clinically unstable hypertension, orthostatic hypotension, and uncontrolled hypertension or hypotension, cerebral or coronary insufficiency, Raynaud's Syndrome, thromboangiitis obliterans, scleroderma, Sjögren's syndrome, renal or hepatic impairment.
  • (2) Subjects with narrow angle glaucoma.
  • (3) Females who are pregnant, breast feeding, or planning a pregnancy during the study.
  • (4) Females of who do not agree to utilize an adequate form of during their participation in the study.
  • (5) Clinical signs of particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) on the face or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia that may interfere with the study evaluations, in the opinion of the Investigator.
  • (6) Presence of ≥3 facial inflammatory lesions of rosacea at screening and baseline.
  • (7) Presence of any skin condition on the face that would interfere with the diagnosis or assessment of rosacea, as determined by the Investigator.
  • (8) Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that would interfere with the study treatments or study assessments.
  • (9) History of drug or alcohol abuse within 12 months prior to the Screening visit.
  • (10 Known or allergies to any component of the study treatment.
  • (11) Use within 12 hours prior to baseline of any topical products including, but not limited to, lotions, creams, ointments, and cosmetics applied to the face (facial cleanser is acceptable).
  • (12) Use 1 week prior to baseline of niacin ≥500 mg/day.
  • (13) Use within 2 weeks prior to baseline of products containing topical , topical retinoids, topical antibiotics, topical anti-inflammatory, topical treatment for rosacea, or topical treatment for acne.
  • (14) Use within 4 weeks prior to baseline of topical immunomodulators, systemic antibiotics, systemic corticosteroids, systemic anti-inflammatory agents, systemic treatment for rosacea, or systemic treatment for acne (other than oral retinoids, which require a 6-month washout).
  • (15) Undergone 4 weeks prior to baseline any dermatologic or surgical procedure on the face.
  • (16) Use within 3 months prior to baseline of any systemic immunomodulators known to have an effect on rosacea.
  • (17) Use within 6 months prior to baseline of any oral retinoids (e.g., isotretinoin) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
  • (18) Undergone 6 months prior to baseline any laser, light-source (e.g. intense pulsed light, photodynamic therapy) or other energy-based therapy to the face.
  • (19) Exposed to excessive UV radiation within 1 week before Screening visit and/or subject is unwilling to refrain from excessive exposure to UV radiation during the course of the study.
  • (20) Current use of monoamine oxidase (MAO) inhibitors, barbiturates, opiates, sedatives, systemic anesthetics, alpha-agonists, cardiac glycosides, beta blockers, other antihypertensive agents, or oxymetazoline (e.g., eye drops, nasal sprays).
  • (21) Subject has participated in a clinical trial within 30 days or in a biologics study within 6 months preceding admission of this study.
  • (22) Previous participation in this study.
  • (23) Inability to communicate well (i.e., language problem, poor mental development, psychiatric illness or poor cerebral function), that may impair the ability to provide written .
  • (24) Subject has any evidence of organ dysfunction, chronic infectious disease, system disorder or has a condition or is in a situation that, in the Investigator's opinion, that may put the subject at significant risk, may confound the study results, or may significantly interferes with the subject's participation in the study.
  • (25) Employees or family members of the research center or Investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,105 participants (actual)

Study arms

  • Active comparator
    Oxymetazoline hydrochloride Cream, 1%

    Oxymetazoline hydrochloride cream, 1%

    Drug: Oxymetazoline Hydrochloride

  • Active comparator
    RHOFADE Cream, 1%

    RHOFADE Cream, 1%

    Drug: Rhofade Cream, 1%

  • Placebo comparator
    Vehicle Cream

    Vehicle cream

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Treatment Success Was Defined as Having a Clinician Erythema Assessment Score at Least 2 Grades Lower Than the Baseline (Day 1 Predose) Value

    The primary efficacy endpoint was the proportion of subjects with treatment success at all time points 3, 6, 9, and 12 hours post-application on Day 29. Treatment success was defined as having CEA score at least 2 grades lower than the baseline (Day 1 pre-dose) value. Clinician Erythema Assessment was measured as (0-clear, 1-almost clear, 2-mild, 3-moderate, 4- severe).

    Time frame: 29 days

07

Results

Posted Jun 23, 2021

Participant flow

Participant flow — Overall Study
MilestoneOxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle Cream
Started379382344
Completed366366327
Not completed131617
Withdrew: Withdrawal by subject555
Withdrew: Adverse event132
Withdrew: Protocol violation035
Withdrew: Use of prohibited therapy112
Withdrew: Lost to follow-up101
Withdrew: Non-compliant with study drug application220
Withdrew: Administrative reasons001
Withdrew: Miscellaneous321

Outcome measures

PrimaryPercentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Treatment Success Was Defined as Having a Clinician Erythema Assessment Score at Least 2 Grades Lower Than the Baseline (Day 1 Predose) Value

The primary efficacy endpoint was the proportion of subjects with treatment success at all time points 3, 6, 9, and 12 hours post-application on Day 29. Treatment success was defined as having CEA score at least 2 grades lower than the baseline (Day 1 pre-dose) value. Clinician Erythema Assessment was measured as (0-clear, 1-almost clear, 2-mild, 3-moderate, 4- severe).

Time frame:
29 days
Reported as:
Count of participants · Participants
Percentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Treatment Success Was Defined as Having a Clinician Erythema Assessment Score at Least 2 Grades Lower Than the Baseline (Day 1 Predose) Value
ParticipantsOxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle Cream
Success787051
Failure271286265
Statistical analysis
  • Oxymetazoline Hydrochloride Cream, 1% vs RHOFADE Cream, 1% · Mean difference (net): 2.7 · 90% CI -2.6 to 8.0
  • Oxymetazoline Hydrochloride Cream, 1% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.04
  • RHOFADE Cream, 1% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.1126

Adverse events

Collected over 2 month adverse event data collection. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxymetazoline Hydrochloride Cream, 1%0/379 (0%)0/379 (0%)61/379 (16.1%)
RHOFADE Cream, 1%0/382 (0%)1/382 (0.3%)60/382 (15.7%)
Vehicle Cream0/344 (0%)1/344 (0.3%)48/344 (14%)
Most frequent serious events
Most frequent serious events
EventOxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle Cream
Clavicle fractureInjury, poisoning and procedural complications0/3790/3821/344
Acute myocardial infarctionCardiac disorders0/3791/3820/344
Most frequent other events
Showing 10 of 69
Most frequent other events
EventOxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle Cream
Application site painGeneral disorders9/37916/38210/344
Application site pruritusGeneral disorders14/37916/3827/344
HeadacheNervous system disorders9/37911/38212/344
Application site erythemaGeneral disorders7/37910/3827/344
Application site reactionGeneral disorders8/3792/3821/344
Application site acneGeneral disorders4/3796/3822/344
Application site drynessGeneral disorders5/3792/3821/344
Upper respiratory tract infectionInfections and infestations0/3790/3823/344
Application site dermatitisGeneral disorders3/3792/3821/344
AcneSkin and subcutaneous tissue disorders3/3790/3820/344

Baseline characteristics

Safety Population also defined as in the Participant Flow

Age, Continuous
Age, Continuous(years)Oxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle CreamTotal
Mean46.9 ± 13.8746.2 ± 14.0147.2 ± 14.5046.8 ± 14.11
Sex: Female, Male
Sex: Female, Male(Participants)Oxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle CreamTotal
Female282284258824
Male979886281
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle CreamTotal
Hispanic or Latino202205182589
Not Hispanic or Latino177177162516
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle CreamTotal
American Indian or Alaska Native0011
Asian1023
Native Hawaiian or Other Pacific Islander0101
Black or African American92415
White3693773371083
More than one race0202
Unknown or Not Reported0000
Baseline Clinical Erythema Assessment Score
Baseline Clinical Erythema Assessment Score(Participants)Oxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle CreamTotal
0-Clear0000
1-Almost Clear0000
2-Mild0000
3-Moderate287292273852
4-Severe929071253
Baseline Subject Self-Assessment
Baseline Subject Self-Assessment(Participants)Oxymetazoline Hydrochloride Cream, 1%RHOFADE Cream, 1%Vehicle CreamTotal
0-No Sign0000
1-Almost Clear0000
2-Mild0000
3-Moderate282287261830
4-Severe979583275
08

Study locations

1 site
  • Site 1
    Lynchburg, Virginia 24501, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jan 2020, 8 months.

Results were first posted in Jun 2021, 1 year 5 months after primary completion.

Of 17 phase 3 interventional studies under Rosacea, half reached primary completion within 11 months of starting (the median); a quarter within 9 and three quarters within 15. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2019
First posted
May 17, 2019
StartActual
Apr 15, 2019
Primary completionActual
Jan 7, 2020
CompletionActual
Feb 27, 2020
Results first posted
Jun 23, 2021
Last update
Jun 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03954444
Lead sponsor
Actavis Inc.
Responsible party
Sponsor
First posted
May 17, 2019
Start date
Apr 15, 2019
Primary completion
Jan 7, 2020
Completion
Feb 27, 2020
Results posted
Jun 23, 2021
Last update
Jun 23, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxymetazoline

Start the discussion